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Abstract
Background: There was a pandemic influenza around the world in 2009 including South Korea since last
pandemic occurred four decades ago. We aimed to evaluate the epidemiological and clinical characteristics of this
infection in childhood.
Methods: We evaluated the epidemiologic characteristics of all the subjects infected with the 2009 H1N1 influenza
A virus (2,971 patients, ≤ 15 years of age), and the clinical and laboratory findings of the inpatients (217 patients,
80 had pneumonia) between 1 September 2009 and 31 January 2010 in a single hospital throughout the
epidemic.
Results: The age distribution of all the subjects was relatively even. Over 90% of cases occurred during a two-
month period. Two hundred and five patients (94.5%) received oseltamivir within 48 h of fever onset, and 97% of
inpatients defervesced within 48 h of medication. The group with pneumonia included more males than females,
and had higher leukocytes counts with lower lymphocyte differentials than the group without pneumonia. The
white blood cell count and lymphocyte differential were associated with the severity of pneumonia. Corticosteroid
treatment for severe pneumonia patients was highly effective in preventing disease progression.
Conclusion: Children of all ages affected with even rates of infection, but males were predominant in pneumonia
patients. Pneumonia patients showed lymphopenia and its severity was associated with the severity of illness. Our
results suggest that the mechanism of lung injury in 2009 H1N1 virus infection may be associated with the host
immune response.
Background
Although influenza virus infection has been a major glo-
bal concern since the pandemic 1918 ‘Spanish flu’,t h e r e
have been no pandemic influenzas for near four decades
after the 1968 ‘Hong Kong flu’. The pandemic 2009
H1N1 influenza A (2009 H1N1) virus infection was
reported first in Mexico in February 2009, and then the
virus spread rapidly worldwide, including in South Korea
[1]. It has been reported that the majority of H1N1
patients were children and young adults and the mortal-
ity rate was not higher than that of seasonal influenza
[2-4]. The majority of patients affected by the 2009
H1N1 virus infection recovered uneventfully, but some
previously healthy patients developed a rapidly progres-
sive pneumonia, leading to acute respiratory distress syn-
drome (ARDS), multi-organ failure, and death [5-7].
With this enigma, the pathogenesis of acute lung injury
(pneumonia) in influenza infections remains unknown
[1,8,9].
In South Korea, the first patient with 2009 H1N1 virus
infection was reported in May, 2009. The number of
patients gradually increased until mid-October, when the
number of patients was overwhelming for a month, and
then gradually decreased, with few people becoming
infected after February, 2010. Owing to sensational reports
of childhood fatality in the mass media and a new diagnos-
tic tool, the real-time reverse transcriptase-polymerase
chain reaction (RT-PCR), we had the opportunity to evalu-
ate patients with 2009 H1N1 virus infection from the
onset of their illness. In addition, during the study period
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ticosteroids and oseltamivir for patients with severe pneu-
monia including rapidly progressive pneumonia [9,10]. In
this study, we evaluated the epidemiological, clinical and
laboratory features of children with 2009 H1N1 virus
infections in a single hospital throughout the epidemic.
Methods
We retrospectively evaluated all patients with 2009 H1N1
virus infection during the pandemic (2,971 patients) for
epidemiologic characteristics, and for clinical characteris-
tics, we reviewed the medical records and chest radio-
graphic findings of 217 children admitted to The Catholic
University of Korea, Daejeon St Mary’sH o s p i t a lb e t w e e n
1 September 2009 and 31 January 2010. The diagnosis of
patients depended on positive results for the 2009 H1N1
virus RT-PCR (AccuPower
™ in Korea, BiONEER, Ala-
meda, CA, USA) through throat swabs.
Although indications for admission were not clearly
defined in this study, the majority of the inpatients were
those who were suspected to have severe disease such as
pneumonia and to have risk factors for severe disease such
as infants and bronchial asthma. However, it might be
possible that excessive concern of parents on fatality of
this infection in part affected on admission of the uncom-
plicated cases. Among the 217 inpatients, we selected
80 patients with pneumonia and 137 patients without
pneumonia, based on the chest radiographs. The chest
radiographic patterns of admitted patients were reviewed
and classified by two pediatricians (KY Lee and JW Rhim)
and one pediatric radiologist (JC Kim). The patients with
chest radiographic patterns that showed increased nodular
densities along the bronchial trees unilaterally or bilater-
ally, were designated the bronchopneumonia group (49
patients). Patients with a distinctive large patch of infiltra-
tion, segmental or lobar consolidations were designated
the segmental/lobar pneumonia group and regarded as
having a severe pneumonia (31 patients). The first day of
fever was regarded as the first day of illness. Among pneu-
monia patients, we tried corticosteroid treatment for 17
patients with severe pneumonia. As for indication of corti-
costeroids (methyprednisolone, MP or prednisolone), the
subjects had severe respiratory distress with hypoxemia at
presentation (12 cases) or during hospitalization (5 cases)
requiring O2 therapy (9,10). We compared the clinical and
laboratory characteristics of the different groups.
The study was approved by the Institutional Review
Board of the Catholic University of Korea, Daejeon St
Mary’s Hospital.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences for Windows version
12.0 (SPSS, Chicago, IL, USA). Continuous variables are
reported as means ± standard deviations. Statistical sig-
nificance was assessed using the Student’s t-test and the
paired t-test for continuous variables, and using the
c
2 test for categorical variables. A P value of < 0.05 was
considered significant for the statistical tests.
Results
Epidemiological features of the patients with 2009 H1N1
virus infection
During the study period, 5,975 children (aged 2 months-
15 years) with influenza-like illness were seen at our
hospital. Among them, the 2,971 patients were positive
by RT-PCR, and 217 patients were admitted to the iso-
lation wards. The hospitalization rate was 7.3%. The
mean age of the patients (2,971 cases) was 7.6 ± 4.1
years of age and the male-to-female ratio was 1.1:1
(1,581/1,390). The age distribution of the patients is
s h o w ni nF i g u r e1 .C h i l d r e no fa l la g eg r o u p se x c e p t
infants had a relatively even rate of infection (Figure 1,
gray bars). The numbers of new patients each week is
shown in Figure 2. There was an explosive pattern, with
over three quarters of the cases occurring during a sin-
gle month (the 43rd-47th weeks of 2009; 18 October
to 14 November). The age distribution and the weekly
case rate of the patients admitted to hospital (217 cases)
are also shown on Figure 1 and 2 (black bars). These
demonstrated similar patterns to those of the total
patient cohort. For hospitalization rates, younger chil-
dren (0-4 years, 9.8%, 75/762) showed higher admission
rates than older children (5-9 years, 8.6%, 104/1216 and
10-15 years, 3.8%, 38/993).
Figure 1 Age distribution of the H1N1 virus infected patients.
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virus infection
In the 217 hospitalized children, the mean age was 6.2 ±
3.7 years, and the male-to-female ratio was 1.6:1 (132/85).
Almost all the patients had a high fever (97.2%) and cough
(92.6%) suggestive of severe infection such as pneumonia
at the time of admission. Most of the patients were pre-
viously healthy although some had underlying diseases and
only 17 patients had underlying disorders (7.8%), including
11 chronic pulmonary diseases (10 patients with bronchial
asthma and one with past history of brochopulmonary dys-
plasia), 4 neuromuscular disorders (two with epilepsy and
two with cerebral palsy), one with chronic liver disease,
and one with nephrotic syndrome. The outcomes for these
patients were uneventful, except for two asthmatic patients
who developed a mild pneumonia. All inpatients received
oseltamivir of the recommended doses for body weight
and a broad-spectrum antibiotic (ampicillin/sulbactam).
Two hundred and five patients (94.5%) received oseltamivir
within 48 h of fever onset. The mean duration of fever
before admission (including the day of admission) was
2.0 ± 0.8 d and 167 patients (77%) defervesced on the next
day. Only seven patients had fever that persisted > 48 h
after oseltamivir treatment. During hospitalization, five
patients showed progressive pneumonia despite early anti-
viral therapy.
According to the initial chest radiographs, 80 patients
had pneumonia and were divided into two groups: the
bronchopneumonia group (49 patients) and the segmen-
tal/lobar pneumonia group (31 patients). In pneumonia
patients, pneumonic infiltrations appeared within 48 h of
fever onset in 68 patients (85%). When we analyzed the
inpatients according to age (0-4 years, 75 patients; 5-9
years, 104 patients; and 10-15 years, 38 patients), the rates
of pneumonia in each age group were 36.0% (27/75),
45.2% (47/104) and 8.8% (6/38), respectively. The severe
pneumonia (segmental/lobar type) was predominant in
the older age groups (14.8% (4/27), 48.9% (23/47) and 50%
(3/6), respectively).
Among the 80 pneumonia patients, 17 patients showed
severe respiratory distress with hypoxemia at presenta-
tion (12 cases) and during their hospital stay (5 cases).
Arterial blood gas analysis was done in 15 patients, and
12 patients showed hypoxemia (PO2 <6 0m m H gi nt h e
room air). These patients received additional corticoster-
oids as soon as possible when indicated; 12 patients
received intravenous MP (10 mg/kg/day, divided two
doses, at presentation, 5 mg/kg/day at next day and then
tapered off within a week) and 5 patients received oral
prednisolone (1 mg/kg/day, divided 3 doses, for 3 days
tapered off within a week). Six patients received early MP
with osetalmivir which is recommended early use, before
the positive RT-PCR results. Interestingly, all patients
except one (age 4 years) were among the 5-9 years age
group, and male patients were predominant (13/17). We
performed serial chest radiographs of some cases in these
patients. A 6-year-old male patient complained of one
day fever and cough, and his initial chest radiograph
showed few pulmonary infiltrations. On the following
morning, he complained of severe dyspnea and showed
chest radiographic infiltrations on right lower lung and
left hilar regions. He had received two doses of oseltami-
vir before the MP treatment (Figure 3A-C). A 7 year-old
male patient was presented with a day fever and severe
cough and had a rapidly progressive pneumonia in which
initial patchy infiltrates on left upper lobe progressed to
total left lung consolidation within 12 h after admission.
He was given three doses of oseltamivir before the MP
treatment (Figure 4A-G). These two patients showed dra-
matic improvements in their clinical symptoms and
radiographic findings within 24 h after MP treatment. A
7-year-old male patient with lobar pneumonia was trea-
ted with oseltamivir, MP and intravenous immunoglobu-
lin (IVIG) treatment. He was admitted with fever, cough
and progressive dyspnea of 2 days, and after MP (10 mg/
kg/day, divided 2 doses) infusion, he showed persistent
dyspnea and slightly aggravated pneumonic consolidation
(Figure 5C). On the following morning, high-dose IVIG
(1 g/kg) was infused for 6 hours. At the time of termina-
tion of IVIG, his clinical symptoms disappeared and a
dramatic improvement of radiographic findings was
observed within 6 hours after IVIG termination (Figure
5A-F). There was no adverse or rebound reaction in any
patient treated with corticosteroids. The clinical symp-
toms of all patients improved within a day and their
pneumonic infiltrations, regardless of severity, ceased
immediately after corticosteroid treatment and disap-
peared within several days without adverse reactions.
Extrapulmonary manifestations (complications) of
H1N1 infection were observed as four cases of febrile
Figure 2 Weekly frequencies of H1N1 virus infected patients.
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Page 3 of 8Figure 3 The chest radiographs of a patients who had progressive pneumonia during hospitalization (male, 6-year old); on admission
(Figure 3-A), before methyprednisolone (MP) treatment (2nd hospital day, Figure 3-B), and 1 day after MP treatment (Figure 3-C).
Figure 4 The chest radiographs of another patient who had rapidly progressive pneumonia during hospitalization (male, 7-year old); on
admission (Figure 4-A), 2nd hospital day a.m. (Figure 4-B), 2nd hospital day p.m. (Figure 4-C), 3 h after MP treatment (Figure 4-D), 15 h
after MP treatment (3rd hospital day, Figure 4-E), and a chest computed tomography finding on 2nd hospital day p.m. (Figure 4-F).
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Page 4 of 8seizure, two cases of urticaria, one case of hepatitis and
one case of myositis, and no cases of encephalopathy.
Laboratory findings of the inpatients with 2009 H1N1
virus infection
When we compared the patients with and without pneu-
monia, and the patients with segmental/lobar pneumonia
versus those with bronchopneumonia, there were signifi-
cant differences in certain parameters between the
groups. Compared with the group without pneumonia,
the males were over-represented in the pneumonia group
(P = 0.001) and longer hospitalizations (P < 0.001), higher
values for hemoglobin (P = 0.03), WBC (P < 0.001) and
CRP (P < 0.001) and lower values for lymphocyte differ-
ential (P < 0.001) (Table 1). The patients with the more
severe type of pneumonia (segmental/lobar pneumonia)
showed a higher mean age (P = 0.001) and leukocyte
count (P = 0.01) and lower lymphocyte differential values
(P < 0.001) compared with the group with bronchopneu-
monia (Table 2). In addition, the severe pneumonia
patients who received corticosteroids (17 cases) had
the highest leukocyte counts and CRP levels, and the
lowest lymphocyte differentials (11 800 ± 3600/mm
3,
3.0 ± 3.1 mg/dL, and 8.8 ± 6.3%, respectively) [10].
Discussion
In this study, we found that children of all ages except
infants had a relatively even rate of infection with the
2009 H1N1 influenza virus. This is in agreement with
other studies showing that few children and young adults
have immunity against a new viral infection [2,11,12].
Our study of all 2009 H1N1 virus-infected children, in a
single hospital, throughout the epidemic may have epide-
miological implications, along with other studies based
on data from admitted patients or gathered during a por-
tion of the pandemic period [11-14]. It has been reported
Figure 5 The chest radiographs of a patient who were treated with MP and intravenous immunoglobulin (IVIG) (male, 7-year old); on
admission (Figure 5-A), before MP treatment (Figure 5-B), after 2 doses of MP infusion (Figure 5-C), just after termination of IVIG
infusion (Figure 5-D), 8 h after IVIG infusion (Figure 5-E), and 3 days after MP and IVIG treatment (Figure 5-F).
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infection tended to be admitted to hospital more fre-
quently than older children or adults, and our results are
compatible with these studies [2,3,6]. It has also been
reported that certain risk factors are related to the likeli-
hood of developing severe illness, including a younger
age and particular underlying diseases, including obesity
[6,7,15,16]. In this study, we did not analyze obesity and
young age as risk factors, and only 17 patients (7.8%) had
underlying diseases. Although the hospitalization rate
was higher among the younger children (0-4 years of
age), in this study, pneumonia and severe pneumonia
were more prevalent in the 5-9-year-old group than in
younger children.
The explosive increase in the infection rate during two
months (mid-October to mid-December) of the study per-
iod may be a typical pattern of spread of an acute respira-
tory viral infectious disease that has a short incubation
period (1-3 days). This pattern is similar to those reported
in other regions of Korea and other countries [3,4,17].
Vaccination against the 2009 H1N1 influenza virus in
Korea started on 18 November, 2009 for school-aged chil-
dren, on 7 December, 2009 for children aged 6 months to
5 years and on 21 December, 2009 for adults with risk
factors, which was after the peak of the epidemic. The
rapid disappearance of the spread of infection might be
the effect of vaccination and the strengthened individual
hygiene, but the epidemiologic pattern suggests that an
unknown herd immunity against a new viral infection
might also be responsible [3,17].
It is reported that patients with 2009 H1N1 virus infec-
tions had a relative leukopenia with lymphopenia [18,19].
However addition to this finding, we found in the present
study that the patients with pneumonia had a higher WBC
count with lower lymphocyte differential, and the more
severely affected patients had the highest WBC with the
lowest lymphocyte differential in the early stages of the
infection (within two days of fever onset). Previous human
studies of H5N1 virus infections have revealed that a
lower lymphocyte count was associated with a poor out-
come [20], and mice infected with influenza viruses
showed a lymphopenia and the H5N1 subtype was asso-
ciated with marked lymphopenia with total lymphoid
depletion [21]. Therefore peripheral lymphocyte may be
associated with the pathogenesis of acute lung injury in
influenza virus infections [9]. Altered CRP and ESR values
were not prominent in 2009 H1N1 virus infections, but
higher CRP values were associated with a more severe
illness.
The male-to-female ratio was 1.1:1 among all patients,
and 1.6:1 among the admitted patients. Furthermore, male
patients were predominant among those with pneumonia
(3:1, 60/80) and those with respiratory distress who
received corticosteroids (3.3:1, 13/17). Other epidemiolo-
gic studies on children have reported a male predomi-
nance [16], but some studies on inpatients have reported a
female predominance [4,7]. These findings suggest that
genetic factors and possibly environmental factors are
Table 1 Clinical and laboratory findings of patients
infected with the 2009 H1N1 virus, with and without
pneumonia
Group No Pneumonia
(n = 137)
Pneumonia
(n = 80)
P
Clinical characteristics
Mean age (y) 6.5 ± 4.0 5.5 ± 3.1 0.04
Male/Female 72/65 60/20 0.001
Duration of fever (d)
Before admission 1.9 ± 0.9 2.0 ± 0.9 NS
Total 2.2 ± 1.0 2.6 ± 0.9 0.006
Hospitalization (d) 4.5 ± 1.4 5.6 ± 1.3 < 0.001
Oseltamivir, < 48 h (n,%)
a 130 (95) 75 (94) NS
Laboratory findings
Haemoglobin (g/dL) 12.5 ± 0.9 12.8 ± 1.0 0.03
Leukocyte (× 10
9/L) 6.5 ± 3.3 8.8 ± 3.7 < 0.001
Neutrophil (%) 59 ± 19 69 ± 20 < 0.001
Lymphocyte (%) 30 ± 17 21 ± 17 < 0.001
Monocyte (%) 10 ± 4 8 ± 4 0.005
Platelet (× 10
9/L) 224 ± 58 241 ± 61 0.04
CRP (mg/dL) 1.2 ± 1.5 2.4 ± 2.5 < 0.001
ESR (mm/h) 16 ± 12 18 ± 13 NS
CRP; C-reactive protein, ESR; erythrocyte sedimentation rate. NS, statistically
non-specific
a Number (%) of patients who received oseltamivir treatment within 48 h of
fever onset.
Table 2 Clinical and laboratory findings according to the
severity of pulmonary lesions
Group Bronchopneumonia
(n = 49)
Segmental/
Lobar
(n = 31)
P
Clinical characteristics
Mean age (y) 4.7 ± 2.9 6.9 ± 2.9 0.001
Male/Female 37/12 23/8 NS
Duration of fever
(d)
2.6 ± 1.0 2.5 ± 1.0 NS
Hospitalization (d) 5.2 ± 1.2 6.2 ± 1.3 0.001
Oseltamivir, < 48 h
(n,%)
46 (94) 29 (94) NS
Laboratory findings
Haemoglobin (g/dL) 12.6 ± 1.0 13.2 ± 0.8 0.006
Leukocyte (× 10
9/L) 8.2 ± 3.5 9.7 ± 3.8 0.01
Neutrophil (%) 64 ± 21 77 ± 13 0.001
Lymphocyte (%) 26 ± 18 14 ± 11 <
0.001
Monocyte (%) 8 ± 3 7 ± 4 NS
Platelet (× 10
9/L) 231 ± 58 255 ± 64 NS
CRP (mg/dL) 2.0 ± 2.1 3.0 ± 2.8 NS
ESR (mm/h) 18 ± 13 16 ± 13 NS
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ciated pneumonia.
Regarding the pathogenesis of lung injury in influenza
virus infections, it has been believed that the viruses from
upper respiratory tract spread to lower lung tissues and
elicit the cytopathic reaction. However, some clinical and
experimental studies have suggested that the innate and/
or cell-mediated immune reaction (T cell) with excessive
production of cytokines of the host may also be responsi-
b l ef o rt h el u n gi n j u r yi ni n f l u e n z av i r u si n f e c t i o n
[9,22-25]. We experienced no intensive care patient in
this series despite large subjects of the study, and it may
be, at least in part, explained by a rapid use of corticos-
teroids on the patients with severe pneumonia [9,10].
Because this pandemic occurred over 40 years after last
pandemic (Hong Kong flu), there have been no con-
trolled-clinical trials for the efficacy of corticosteroids on
influenza virus infections, although yearly seasonal influ-
enza and small cases of sporadic H5N1 avian influenza
virus infection have occurred during inter-pandemic per-
iod. The beneficial effect of corticosteroids in pneumonia
caused by influenza virus infections may have resulted
from reduction of systemic inflammation caused by
immune cells and cytokines [26,27]. Our treatment policy
which needs to be proven by controlled clinical studies in
coming pandemics or in other influenza virus infections,
may help to reduce the morbidity and possibly prevent
the progression to fatal pneumonia [9,10]. We have
reviewed the rationale of our corticosteroid treatment
and the host immune responses to viral insults in influ-
enza virus infections, and proposed a new concept for
the pathogenesis of acute lung injury in influenza virus
infections, using a ‘protein homeostasis system’ of the
host [9].
It has been reported that antiviral therapy (oseltamivir)
is effective in the acute stages of influenza infection,
including H1N1 virus infection in humans and experi-
mental animals [4,28]. In agreement with this, we found
that the majority of patients (97%) defervesced within 48
h after medication and most pneumonic infiltrations in
pneumonia patients had improved at discharge.
There are some limitations to this study. Compared with
other studies, we had many uncomplicated inpatients
owing to flexibility of our admission policy. Because we
did not perform extensive microbiological testing, such as
viral cultures, paired-sample serologic studies and PCR for
other pathogens, we cannot rule out the possibility of co-
infection with other respiratory pathogens.
Conclusions
In pandemic 2009 H1N1 virus infections, children of all
ages were evenly affected, and males were predominant
in pneumonia patients. Early antiviral treatment was very
effective in inducing rapid defervescence for the patients.
The patients with 2009 H1N1 infections showed lympho-
penia, and its severity was associated with the severity of
the illness in the early stages. Together this finding, the
rapid improvement in clinical signs and the prompt reso-
lution of severe pneumonic consolidations after immune-
modulator (corticosteroid and IVIG) treatment suggest
that the mechanisms of lung injury in this infection may
be associated with the cell-mediated immune response of
the host, rather than virus-induced cytopathies.
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